Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection
Condition(s):Bacteremia Caused by Gram-Negative BacteriaLast Updated:January 23, 2020Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Bacteremia Caused by Gram-Negative BacteriaLast Updated:January 23, 2020Not yet recruiting
Condition(s):Pseudomonas Infections; Pseudomonas AeruginosaLast Updated:April 27, 2018Unknown status
Condition(s):Pseudomonas Aeruginosa; Pneumonia; Hematologic MalignancyLast Updated:December 17, 2020Recruiting
Condition(s):Ventilator-associated PneumoniaLast Updated:April 8, 2020Recruiting
Condition(s):Serious InfectionLast Updated:February 6, 2020Not yet recruiting
Condition(s):Ventilator Associated Pneumonia; Antibiotic Resistant InfectionLast Updated:April 20, 2020Active, not recruiting
Condition(s):PharmacokineticsLast Updated:September 10, 2020Completed
Condition(s):Other Infectious DiseasesLast Updated:October 22, 2020Recruiting
Condition(s):Gram-Negative Bacterial InfectionsLast Updated:October 2, 2019Completed
Condition(s):Nosocomial InfectionLast Updated:December 22, 2020Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.